Overview

PURE Bioscience, Inc. filed its Form 10-Q for the quarterly period ended January 31, 2026. This quarterly report includes unaudited condensed consolidated financial statements and management’s discussion and analysis for the three and six months ended January 31, 2026. The company is a non-accelerated filer, a smaller reporting company, and not an emerging growth company.

Key Financial Highlights

• Common Stock Outstanding: As of March 16, 2026, the company had 111,886,473 shares of common stock (\$0.01 par value) outstanding.
• Stockholders’ Deficiency: The company reported a stockholders’ deficiency of \$6,273,000 as of January 31, 2026, which widened from \$5,116,000 as of July 31, 2025. This increasing deficit is an important trend for shareholders to monitor.
• Net Loss: For the six months ended January 31, 2026, PURE Bioscience recorded a net loss of \$1,249,000. For the three months ended January 31, 2026, the net loss was \$798,000. The company continues to operate at a loss.
• Accumulated Deficit: The accumulated deficit increased to \$140,243,000 as of January 31, 2026, up from \$138,994,000 at July 31, 2025, indicating ongoing operational losses.
• Share-Based Compensation: During the six months ended January 31, 2026, the company recognized \$92,000 in share-based compensation expense related to stock options, showing continued use of equity incentives.
• Cash Position and Assets: Total assets as of July 31, 2025, stood at \$1,058,000. The balance as of January 31, 2026, was not explicitly provided, but the ongoing losses and deficiency suggest liquidity is a risk factor.
• Cash Paid for Taxes: The company paid \$4,000 in income taxes during the six months ended January 31, 2026.

Other Key Disclosures

• Issuer Status: PURE Bioscience is not a well-known seasoned issuer, not required to file reports under Section 13 or 15(d), and not a shell company.
• SEC Compliance: The company has filed all required reports for the past 12 months and submitted all required Interactive Data Files.
• Preferred Stock: No preferred stock was outstanding as of January 31, 2026, or July 31, 2025.
• Risk Factors, Legal Proceedings, Defaults: These sections are included in the 10-Q, but no specific risk factors, legal matters, or defaults upon senior securities are highlighted in the sections made available.

Potentially Price-Sensitive Information and Shareholder Implications

• Continuing Operating Losses and Growing Deficit: The persistent net losses and increasing stockholders’ deficiency are significant. These trends could impact market sentiment and the company’s ability to raise capital or meet listing requirements, making this disclosure potentially price sensitive.
• Liquidity and Solvency Concerns: With total assets just over \$1 million (as of July 31, 2025) and an increasing deficit, PURE Bioscience may face liquidity challenges. Investors should watch for future disclosures regarding cash management, debt covenants, or capital raising activities.
• Shareholder Dilution Risk: The company continues to use share-based compensation, which may result in further dilution of existing shareholders if additional equity is issued to raise funds or compensate employees.

Conclusion

PURE Bioscience’s Q2 2026 report underlines the company’s ongoing financial challenges, specifically its continuing net losses and growing stockholders’ deficiency. These factors, together with the company’s modest asset base, highlight significant risks to shareholders, particularly regarding future dilution or the ability to continue as a going concern. Investors should closely monitor future filings for updates on liquidity, strategic initiatives, and any potential changes in capital structure that may be required to support operations.